| | DVTb
| PEb
| OTEb
|
|---|
| | Before | After | Before | After | Before | After |
|---|
OR (95% CI) | HR (95% CI) | OR (95% CI) | HR (95% CI) | OR (95% CI) | HR (95% CI) |
|---|
Overall
|
1.6 (1.3-1.9)
|
3.6 (3.1-4.1)
|
1.8 (1.3-2.6)
|
4.3 (3.2-5.7)
|
1.5 (1.2-1.8)
|
2.4 (2.0-2.8)
|
P-value
c
|
<0.001
|
<0.001
|
<0.001
|
<0.001
|
<0.001
|
<0.001
|
Effect measure modifiers
|
Atherosclerosis | Yes | ns | 2.0 (1.5-2.6) | ns | ns | ns | ns |
No | ns | 4.1 (3.5-4.9) | ns | ns | ns | ns |
P-valuec
| 0.384 | <0.001 | 0.112 | 0.275 | 0.364 | 0.100 |
Central venous catheterd
| Yes | ns | ns | ns | 0.7 (0.1-6.0) | ns | ns |
No | ns | ns | ns | 4.9 (3.7-6.5) | ns | ns |
P-value c
| 0.134 | 0.081 | 0.977 | 0.161 | 0.440 | 0.882 |
Diabetes | Yes | 1.1 (0.8-1.5) | 2.4 (1.9-3.1) | ns | ns | ns | ns |
No | 1.8 (1.4-2.2) | 4.2 (3.6-5.1) | ns | ns | ns | ns |
P-value c
| 0.003 | <0.001 | 0.280 | 0.332 | 0.181 | 0.108 |
High-risk surgerye
| Yes | ns | 1.4 (0.7-2.8) | ns | 1.2 (0.4-3.7) | ns | ns |
No | ns | 3.8 (3.3-4.4) | ns | 4.7 (3.5-6.3) | ns | ns |
| | P-value c
| 0.129 | <0.001 | 0.698 | 0.030 | 0.714 | 0.387 |
History of CVDf
| Yes | 1.1 (0.8-1.5) | 2.0 (1.6-2.6) | ns | 2.5 (1.5-4.0) | 1.0 (0.7-1.4) | 1.6 (1.2-2.2) |
No | 1.8 (1.4-2.2) | 4.7 (3.9-5.6) | ns | 5.2 (3.6-7.4) | 1.7 (1.3-2.1) | 2.7 (2.2-3.3) |
P-value c
| 0.002 | <0.001 | 0.366 | 0.005 | 0.001 | <0.001 |
Kidney disease | Yes | ns | 1.8 (1.3-2.5) | ns | 1.3 (0.7-2.3) | ns | 1.3 (0.8-2.2) |
No | ns | 4.0 (3.4-4.6) | ns | 5.2 (3.8-7.2) | ns | 2.5 (2.1-3.0) |
| | P-value c
| 0.292 | <0.001 | 0.940 | <0.001 | 0.343 | 0.014 |
-
aAll models adjusted for age at index date (matching factor), sex, kidney disease and stratified by important effect measure modifiers. Odds ratios compared risk of a VTE in the 12 months before diagnosis (or index date) and hazard ratios compared risk of VTE in the 12 months after diagnosis (or index date). Results from SEER-Medicare Data (1991–2003). RCC Patients (n = 11,950); Non-Cancer Control Group (n = 11,918).
-
bDVT = deep vein thrombosis, PE = pulmonary embolism, OTE = other thrombolic event. OTE includes: central retinal vein occlusion, venous tributary (branch) occlusion, nonpyogenic thrombosis of intracranial venous sinus, phlebitis/thrombophlebitis of superficial vessels of lower extremities, phlebitis/thrombophlebitis of superficial veins of upper extremities, phlebitis/thrombophlebitis of other sites, gout with other specified manifestations, Budd-Chiari syndrome, venous embolism/thrombosis of renal vein and portal vein thrombosis.
-
cP-Value for the difference between stratum specific estimates.
-
dCentral venous catheter (CVC) in the 12 months after diagnosis. CVCs that occurred less than 30 days before a TE event were excluded.
-
eHigh-risk surgery = cardiac or vascular surgeries in the year after index date or RCC diagnosis. Procedures that happened less than 30 days before a TE event were excluded because of the nature of Medicare claims (Date ranges, rather than exact dates, are used for procedures and we wanted to make sure that the procedure was not part of the treatment for the TE outcome of interest.).
-
fHistory of CVD = any of the following CVD events in the year before the analysis period: MI, IS, onset congestive heart failure, angina, or TIA (analysis period = 12 months before diagnosis or index date or 12 months after diagnosis or index date).
- ns = no statistically significant difference between strata.
